Rosalind Advisors’s CG Oncology CGON Stock Holding History

Rosalind Advisors’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Buy	+31,000	New	+$2.03M	0.14%	31

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rosalind Advisors's CGON Position: Q2 2026 in Review

Rosalind Advisors sold out of CG Oncology (CGON) in Q2 2026, closing a stake of 100,000 shares — an estimated $6.54M sold.

Rosalind Advisors first reported a position in CGON in Q2 2025 and held it in 4 quarters. The position peaked at $12.5M in Q4 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Rosalind Advisors reported no remaining CG Oncology position as of Q2 2026 after selling out during the quarter.
Rosalind Advisors sold 100,000 CG Oncology shares in Q2 2026, an estimated $6.54M.
Rosalind Advisors first reported a position in CG Oncology in Q2 2025 and held it in 4 quarters.
Rosalind Advisors's CG Oncology position peaked at $12.5M in Q4 2025.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.